company background image
V9Z logo

Aceragen DB:V9Z Stock Report

Last Price

€0.24

Market Cap

€2.0m

7D

-1.6%

1Y

-97.2%

Updated

05 Sep, 2023

Data

Company Financials +

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

V9Z Stock Overview

Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States.

V9Z fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Aceragen, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aceragen
Historical stock prices
Current Share Price€0.24
52 Week High€11.09
52 Week Low€0.24
Beta1.2
1 Month Change-64.96%
3 Month Change-84.00%
1 Year Change-97.16%
3 Year Change-99.14%
5 Year Change-99.82%
Change since IPO-99.98%

Recent News & Updates

Recent updates

Shareholder Returns

V9ZDE BiotechsDE Market
7D-1.6%-1.3%0.4%
1Y-97.2%-23.2%0.4%

Return vs Industry: V9Z underperformed the German Biotechs industry which returned -5.5% over the past year.

Return vs Market: V9Z underperformed the German Market which returned 10.9% over the past year.

Price Volatility

Is V9Z's price volatile compared to industry and market?
V9Z volatility
V9Z Average Weekly Movement30.6%
Biotechs Industry Average Movement5.7%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.5%

Stable Share Price: V9Z's share price has been volatile over the past 3 months.

Volatility Over Time: V9Z's weekly volatility (31%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
198926John Taylorhttps://www.aceragen.com

Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich’s Ataxia.

Aceragen, Inc. Fundamentals Summary

How do Aceragen's earnings and revenue compare to its market cap?
V9Z fundamental statistics
Market cap€2.02m
Earnings (TTM)-€38.03m
Revenue (TTM)€6.79m

0.3x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
V9Z income statement (TTM)
RevenueUS$7.33m
Cost of RevenueUS$15.40m
Gross Profit-US$8.06m
Other ExpensesUS$32.98m
Earnings-US$41.05m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-4.88
Gross Margin-110.00%
Net Profit Margin-559.86%
Debt/Equity Ratio1.3%

How did V9Z perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.